However, given that CLL cells are chronically stimulated in vivo through their BCR (27–29) and that Ag receptor stimulation prevents upregulation of S1PR1 expression on normal T cells in lymph nodes, another possible explanation for the mobilizing effect of BCR pathway inhibitors presents itself. This evidence concerns the gene S1PR1 and B-cell chronic lymphocytic leukemia.